The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be ...
The US fiscal year ended this week amid questions about the billion dollars in Congressionally-appropriated foreign assistance, while new strategies for HIV research at the National Institutes of ...
There is no shortage of global health news this week. Against the backdrop of the UN General Assembly (UNGA 81), this issue covers efforts to reshape the global health architecture through the Accra ...
Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that ...
Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement ...
HIV prevention research must be conducted in collaboration with the communities it intends to serve; decisions about study design, participant populations and locations, conduct, and future access ...
Preparing people affected by HIV to preserve and expand research The US HIV Cure Academy connects people affected by HIV with leading researchers to explore the latest HIV cure strategies and equip ...
Significant challenges persist in the wake of cuts to PEPFAR funding and programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services ...
This infographic, with data featured in amfAR’s PEPFAR Pulse study, examines the percentage change in PEPFAR prevention expenditures from FY24 to FY25. Significant challenges persist in the wake of ...
Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, ...
A first-in-class once-weekly oral combination of islatravir plus lenacapavir achieved viral suppression as effectively as daily oral antiretroviral therapy (ART) at week 48 in the ISLEND trial, ...
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results